Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability

PURPOSE: The programmed death ligand 1 (PD-L1) SP142 assay with a 1% immune cell (IC) cutoff is approved for the selection of advanced triple-negative breast cancer (TNBC) patients for atezolizumab treatment. We aimed to evaluate the interobserver concordance of PD-L1 scoring and inter-assay variabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Soomin, Woo, Ji Won, Kim, Hyojin, Cho, Eun Yoon, Kim, Ahrong, Kim, Jee Yeon, Kim, Chungyeul, Lee, Hee Jin, Lee, Ji Shin, Bae, Young Kyung, Kwon, Youngmee, Kim, Wan Seop, Park, So Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250096/
https://www.ncbi.nlm.nih.gov/pubmed/34128367
http://dx.doi.org/10.4048/jbc.2021.24.e29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250096/
https://www.ncbi.nlm.nih.gov/pubmed/34128367
http://dx.doi.org/10.4048/jbc.2021.24.e29

Ejemplares similares